This study firstly associates PRRX1 loss-of-function variation with AF and PDA in humans, which suggests that AF and PDA may share a common basis of anomalous cardiovascular development in a subset of cases, implying potential implications for early precise prophylaxis and improved prognostic risk stratification of patients affected with AF and PDA. This evidence concerns the gene PRRX1 and atrial fibrillation.